These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 22982733

  • 21. A new respirable form of rifampicin.
    Son YJ, McConville JT.
    Eur J Pharm Biopharm; 2011 Aug; 78(3):366-76. PubMed ID: 21324356
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K, Katona G, Csóka I, Ambrus R.
    J Pharm Biomed Anal; 2018 Jan 30; 148():73-79. PubMed ID: 28965047
    [Abstract] [Full Text] [Related]

  • 24. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV, Jain RR, Bannalikar AS, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2016 Apr 30; 29(2):179-95. PubMed ID: 26406162
    [Abstract] [Full Text] [Related]

  • 25. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
    Fabio K, Curley K, Guarneri J, Adamo B, Laurenzi B, Grant M, Offord R, Kraft K, Leone-Bay A.
    AAPS PharmSciTech; 2015 Dec 30; 16(6):1299-306. PubMed ID: 25776985
    [Abstract] [Full Text] [Related]

  • 26. Inhalable formulations of rifampicin by spray drying of supersaturated aqueous solutions.
    Berkenfeld K, McConville JT, Lamprecht A.
    Eur J Pharm Biopharm; 2020 Aug 30; 153():14-22. PubMed ID: 32446961
    [Abstract] [Full Text] [Related]

  • 27. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance.
    Yang Y, Yang Z, Ren Y, Mei X.
    Drug Deliv; 2014 Sep 30; 21(6):480-6. PubMed ID: 24491208
    [Abstract] [Full Text] [Related]

  • 28. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
    Momin MAM, Tucker IG, Das SC.
    Drug Dev Ind Pharm; 2019 Jul 30; 45(7):1205-1213. PubMed ID: 30990097
    [Abstract] [Full Text] [Related]

  • 29. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F, Lejeune M, Edge S.
    Drug Dev Ind Pharm; 2011 Jan 30; 37(1):24-32. PubMed ID: 20738180
    [Abstract] [Full Text] [Related]

  • 30. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS, Kim JH, Jin SG, Kim DW, Kim JO, Yong CS, Youn YS, Oh KT, Woo JS, Choi HG.
    Pharm Dev Technol; 2018 Feb 30; 23(2):158-166. PubMed ID: 28612675
    [Abstract] [Full Text] [Related]

  • 31. Pure insulin highly respirable powders for inhalation.
    Balducci AG, Cagnani S, Sonvico F, Rossi A, Barata P, Colombo G, Colombo P, Buttini F.
    Eur J Pharm Sci; 2014 Jan 23; 51():110-7. PubMed ID: 23981336
    [Abstract] [Full Text] [Related]

  • 32. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
    Yu H, Teo J, Chew JW, Hadinoto K.
    Int J Pharm; 2016 Feb 29; 499(1-2):38-46. PubMed ID: 26757148
    [Abstract] [Full Text] [Related]

  • 33. Effect of Lipidic Excipients on the Particle Properties and Aerosol Performance of High Drug Load Spray Dried Particles for Inhalation.
    Shetty N, Hau J, Yanez E, Shur J, Cheng J, Sun CC, Nagapudi K, Narang A.
    J Pharm Sci; 2022 Apr 29; 111(4):1152-1163. PubMed ID: 34506865
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Synergistic combination of antimicrobial peptide and isoniazid as inhalable dry powder formulation against multi-drug resistant tuberculosis.
    Shao Z, Tam KK, Achalla VPK, Woon ECY, Mason AJ, Chow SF, Yam WC, Lam JKW.
    Int J Pharm; 2024 Apr 10; 654():123960. PubMed ID: 38447778
    [Abstract] [Full Text] [Related]

  • 37. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
    Momin MAM, Tucker IG, Doyle CS, Denman JA, Sinha S, Das SC.
    Int J Pharm; 2018 Apr 25; 541(1-2):26-36. PubMed ID: 29458207
    [Abstract] [Full Text] [Related]

  • 38. Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles.
    Marasini N, Sheikh Z, Wong CYJ, Hosseini M, Spicer PT, Young P, Xin Ong H, Traini D.
    Int J Pharm; 2022 Aug 25; 624():121989. PubMed ID: 35809834
    [Abstract] [Full Text] [Related]

  • 39. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
    Young PM, Salama RO, Zhu B, Phillips G, Crapper J, Chan HK, Traini D.
    Drug Dev Ind Pharm; 2015 May 25; 41(5):859-65. PubMed ID: 24811055
    [Abstract] [Full Text] [Related]

  • 40. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, Russo P.
    Int J Pharm; 2012 Apr 15; 426(1-2):100-107. PubMed ID: 22301426
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.